SCHEMBL4833344

SCHEMBL4833344

CCCc1ccc(S(=O)(=O)Nc2ccc(N3CN=c4occc4=C3N)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ HSP90AA1 P07900 2/20 0.41
▸ HSP90AB1 P08238 2/20 0.41
▸ NAMPT P43490 1/20 0.41
▸ FFAR4 Q5NUL3 2/20 0.41
▸ FFAR1 O14842 1/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ KIT P10721 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ ATM Q13315 1/20 0.40
▸ NR1I2 O75469 1/20 0.38
▸ HTR6 P50406 4/20 0.38
▸ DRD2 P14416 3/20 0.38
▸ DRD3 P35462 3/20 0.38
▸ HTR2A P28223 2/20 0.38
▸ HTR2C P28335 2/20 0.38
▸ UCHL1 P09936 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4833709 0.94 LMNA (0.51) LMNATP53HSP90AA1HSP90AB1FFAR4
SCHEMBL4830936 0.92 ALDH1A1 (0.49) LMNATP53FFAR4ALDH1A1KIT
SCHEMBL4834285 0.86 SMN1; SMN2 (0.48) LMNATP53ALDH1A1MAPTCYP1A2
SCHEMBL4834402 0.85 ALDH1A1 (0.49) LMNAFFAR4FFAR1ALDH1A1MAPT
SCHEMBL4833946 0.85 KEAP1 (0.46) LMNAFFAR4ALDH1A1MAPTNR1I2
SCHEMBL4833803 0.84 POLB (0.47) LMNAALDH1A1KITMAPTDRD2
SCHEMBL4831475 0.84 KMT2A (0.52) LMNAALDH1A1MAPTATMCYP2C9
SCHEMBL4834019 0.84 ALDH1A1 (0.51) LMNANAMPTFFAR4FFAR1ALDH1A1
SCHEMBL4833614 0.83 POLB (0.53) LMNATP53ALDH1A1MAPTCYP2C9
SCHEMBL4829080 0.82 TP53 (0.44) LMNATP53ALDH1A1MAPTHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US claimed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US claimed
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF ADAMS JERRY LEROY 2008-11-20 — — US disclosed
US-7427623-B2 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof SMITHKLINE BEECHAM CORPORATION (US) 2008-09-23 — — US disclosed
US-20050004142-A1 Chemical compounds SMITHKLINE BEECHAM CORPORATION 2005-01-06 — — US disclosed
EP-1425284-A2 FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2004-06-09 — — EP disclosed
WO-2003022852-A2 FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004142-A1 Chemical compounds TIE1, KDR, TEK LMNA 4230/4885TP53 54/4885HSP90AA1 2619/4885
US-20080287466-A1 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF TIE1, TEK, KDR LMNA 4131/4885TP53 144/4885HSP90AA1 3603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback